Allan H Smith1, Guillermo Marshall2, Taehyun Roh1, Catterina Ferreccio3, Jane Liaw1, Craig Steinmaus1. 1. Arsenic Health Effects Research Group, School of Public Health, University of California, Berkeley, CA. 2. Departamento de Estadística, Facultad de Matemáticas, Pontificia Universidad Católica de Chile, Santiago, Chile. 3. Advanced Center for Chronic Diseases, Escuela de Medicina, Pontificia Universidad Católica de Chile, Santiago, Chile.
Abstract
Background: Region II in northern Chile (population 442 570) experienced a sudden major increase in arsenic water concentrations in 1958 in the main city of Antofagasta, followed by a major reduction in exposure when an arsenic removal plant was installed in 1970. It provides a unique opportunity to study latency effects of exposure to arsenic, and this is the first study with mortality data up to 40 years after exposure reduction. Methods: We previously identified high mortality rates in Region II up to the year 2000. Here we present rate ratios (RRs) for Region II compared with all the rest of Chile from 2001 to 2010, and with unexposed Region V (population 1 539 852) for all years from 1950 to 2010. All statistical tests were one-sided. Results: From 2001 to 2010, comparing Region II with the rest of Chile, lung and bladder mortality were still greatly elevated (RR = 3.38, 95% confidence interval [CI] = 3.19 to 3.58, P < .001 for lung cancer in men; RR = 2.41, 95% CI = 2.20 to 2.64, P < .001 for lung cancer in women; RR = 4.79, 95% CI = 4.20 to 5.46, P < .001 for bladder cancer in men; RR = 6.43, 95% CI = 5.49 to 7.54, P < .001 for bladder cancer in women). Kidney cancer mortality was also elevated (RR = 1.75, 95% CI = 1.49 to 2.05, P < .001 for men; RR = 2.09, 95% CI = 1.69 to 2.57, P < .001 for women). Earlier short latency acute myocardial infarction mortality increases had subsided. Conclusions: Lung, bladder, and kidney cancer mortality due to arsenic exposure have very long latencies, with increased risks manifesting 40 years after exposure reduction. Our findings suggest that arsenic in drinking water may involve one of the longest cancer latencies for a human carcinogen.
Background: Region II in northern Chile (population 442 570) experienced a sudden major increase in arsenic water concentrations in 1958 in the main city of Antofagasta, followed by a major reduction in exposure when an arsenic removal plant was installed in 1970. It provides a unique opportunity to study latency effects of exposure to arsenic, and this is the first study with mortality data up to 40 years after exposure reduction. Methods: We previously identified high mortality rates in Region II up to the year 2000. Here we present rate ratios (RRs) for Region II compared with all the rest of Chile from 2001 to 2010, and with unexposed Region V (population 1 539 852) for all years from 1950 to 2010. All statistical tests were one-sided. Results: From 2001 to 2010, comparing Region II with the rest of Chile, lung and bladder mortality were still greatly elevated (RR = 3.38, 95% confidence interval [CI] = 3.19 to 3.58, P < .001 for lung cancer in men; RR = 2.41, 95% CI = 2.20 to 2.64, P < .001 for lung cancer in women; RR = 4.79, 95% CI = 4.20 to 5.46, P < .001 for bladder cancer in men; RR = 6.43, 95% CI = 5.49 to 7.54, P < .001 for bladder cancer in women). Kidney cancer mortality was also elevated (RR = 1.75, 95% CI = 1.49 to 2.05, P < .001 for men; RR = 2.09, 95% CI = 1.69 to 2.57, P < .001 for women). Earlier short latency acute myocardial infarction mortality increases had subsided. Conclusions: Lung, bladder, and kidney cancer mortality due to arsenic exposure have very long latencies, with increased risks manifesting 40 years after exposure reduction. Our findings suggest that arsenic in drinking water may involve one of the longest cancer latencies for a human carcinogen.
Authors: Craig Steinmaus; Catterina Ferreccio; Johanna Acevedo; Yan Yuan; Jane Liaw; Viviana Durán; Susana Cuevas; José García; Rodrigo Meza; Rodrigo Valdés; Gustavo Valdés; Hugo Benítez; Vania VanderLinde; Vania Villagra; Kenneth P Cantor; Lee E Moore; Saida G Perez; Scott Steinmaus; Allan H Smith Journal: Cancer Epidemiol Biomarkers Prev Date: 2014-05-23 Impact factor: 4.254
Authors: Yan Yuan; Guillermo Marshall; Catterina Ferreccio; Craig Steinmaus; Steve Selvin; Jane Liaw; Michael N Bates; Allan H Smith Journal: Am J Epidemiol Date: 2007-09-17 Impact factor: 4.897
Authors: Catterina Ferreccio; Allan H Smith; Viviana Durán; Teresa Barlaro; Hugo Benítez; Rodrigo Valdés; Juan José Aguirre; Lee E Moore; Johanna Acevedo; María Isabel Vásquez; Liliana Pérez; Yan Yuan; Jane Liaw; Kenneth P Cantor; Craig Steinmaus Journal: Am J Epidemiol Date: 2013-06-13 Impact factor: 4.897
Authors: Cristina M Ghiuzeli; Miroslav Stýblo; Jesse Saunders; Anthony Calabro; Daniel Budman; Steven Allen; Craig Devoe; Radhika Dhingra Journal: Leuk Lymphoma Date: 2021-10-25
Authors: Taehyun Roh; Craig Steinmaus; Guillermo Marshall; Catterina Ferreccio; Jane Liaw; Allan H Smith Journal: Am J Epidemiol Date: 2018-11-01 Impact factor: 4.897
Authors: Alison K Krajewski; Monica P Jimenez; Kristen M Rappazzo; Danelle T Lobdell; Jyotsna S Jagai Journal: J Expo Sci Environ Epidemiol Date: 2021-03-10 Impact factor: 5.563